Resistance to Two Heterologous Neurotropic Oncolytic Viruses, Semliki Forest Virus and Vaccinia Virus, in Experimental Glioma

ABSTRACT Attenuated Semliki Forest virus (SFV) may be suitable for targeting malignant glioma due to its natural neurotropism, but its replication in brain tumor cells may be restricted by innate antiviral defenses. We attempted to facilitate SFV replication in glioma cells by combining it with vaccinia virus, which is capable of antagonizing such defenses. Surprisingly, we found parenchymal mouse brain tumors to be refractory to both viruses. Also, vaccinia virus appears to be sensitive to SFV-induced antiviral interference.

[1]  M. Vähä-Koskela,et al.  Interferon-β sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  L. Hwang,et al.  Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  A. N. van den Pol,et al.  Vesicular Stomatitis Virus Has Extensive Oncolytic Activity against Human Sarcomas: Rare Resistance Is Overcome by Blocking Interferon Pathways , 2011, Journal of Virology.

[4]  R. Stupp,et al.  Neuro-oncology, a decade of temozolomide and beyond , 2010, Expert review of anticancer therapy.

[5]  R. Welsh,et al.  Heterologous immunity between viruses , 2010, Immunological reviews.

[6]  H. Atkins,et al.  Synergistic interaction between oncolytic viruses augments tumor killing. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  J. Bell,et al.  United virus: the oncolytic tag-team against cancer! , 2010, Cytokine & growth factor reviews.

[8]  T. Wu,et al.  Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  K. Anderson,et al.  Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity , 2010, Nature Medicine.

[10]  M. Vähä-Koskela,et al.  Intravenously Administered Alphavirus Vector VA7 Eradicates Orthotopic Human Glioma Xenografts in Nude Mice , 2010, PloS one.

[11]  S. Russell,et al.  Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways , 2009, Expert opinion on biological therapy.

[12]  C. Nutt,et al.  Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide , 2009, Clinical Cancer Research.

[13]  E. Zúñiga,et al.  Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections. , 2008, Cell host & microbe.

[14]  Z. Guo,et al.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. , 2008, Biochimica et biophysica acta.

[15]  W. Vandertop,et al.  Differential Effects of Combined Ad5-Δ24RGD and Radiation Therapy in In vitro versus In vivo Models of Malignant Glioma , 2007, Clinical Cancer Research.

[16]  Tiina Wahlfors,et al.  Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models , 2007, International journal of cancer.

[17]  C. Uyttenhove,et al.  Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor1 , 2007, The Journal of Immunology.

[18]  S. Krishnamurthy,et al.  Differentially Regulated Interferon Response Determines the Outcome of Newcastle Disease Virus Infection in Normal and Tumor Cell Lines , 2006, Journal of Virology.

[19]  Kevin Camphausen,et al.  Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  John Yin,et al.  Quantifying Viral Propagation in Vitro: Toward a Method for Characterization of Complex Phenotypes , 2001, Biotechnology progress.